Biotech Values

[DewDiligence]

Good decision, IMO. PFE’s share price not only values the pipeline at close to zero, but also discounts the continuing EPS gain from post-merger cost-cutting. All told, the Wyeth acquisition will boost PFE’s profitability by more than a Lipitor-sized drug would be able to do.